Two adalimumab biosimilars (Amjevita and Imraldi) worked as well for moderate to severe psoriasis as the original brand-name ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...

For plaque psoriasis, you’ll start with a loading dose of 80 mg of Humira. One week after your loading dose, you’ll start taking 40 mg every other week. Humira is available in a starter kit ...

That's not necessarily what the data say, but in the clinic, I feel like adalimumab is still a really great initial option." For patients with skin-only psoriasis and no insurance issues ...

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

Symptoms can include itching, pain, or swelling. Humira can also cause new or worsen psoriasis, a condition Humira is approved to treat. Psoriasis is a skin condition that causes symptoms such as ...

Adalimumab was the third TNF inhibitor to be approved for psoriasis, but has been gaining momentum in the market against etanercept, owing to superior efficacy data from clinical trials (Psoriasis ...

Despite being the most widely used drug in the US, Humira, known for its effectiveness in treating conditions such as rheumatoid arthritis, plaque psoriasis, Crohn's disease, and ulcerative ...

Opens in a new tab or window Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the ...